149 related articles for article (PubMed ID: 8605711)
1. Plasminogen activator inhibitor-1 and peritoneal transport in diabetic and non-diabetic peritoneal dialysis patients.
Lin JJ; Parton L; Bereket G; Wadhwa NK
Clin Nephrol; 1995 Nov; 44(5):310-5. PubMed ID: 8605711
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor-1 and peritoneal transport in peritoneal dialysis patients.
Wadhwa NK; Lin JJ; Parton L; Bereket G; Cabralda T; Suh H
Adv Perit Dial; 1996; 12():33-8. PubMed ID: 8865868
[TBL] [Abstract][Full Text] [Related]
3. Increased peritoneal solute transport in diabetic peritoneal dialysis patients.
Lin JJ; Wadhwa NK; Suh H; Cabralda T; Patlak CS
Adv Perit Dial; 1995; 11():63-6. PubMed ID: 8534740
[TBL] [Abstract][Full Text] [Related]
4. Correlations between plasminogen activator inhibitor-1 and peritoneal transport in pediatric CCPD patients.
Lin JJ; Singhal K; Parton L; Cascio C; Patlak CS; Stewart CL
Perit Dial Int; 1995; 15(6):246-51. PubMed ID: 7578502
[TBL] [Abstract][Full Text] [Related]
5. [Extended assessment of peritoneal transport kinetics of substances and water as an important element of integrated dialysis care].
Baczyński D; Antosiewicz S; Waniewski J; Marciniak M; Wańkowicz Z
Pol Merkur Lekarski; 2004 Aug; 17(98):110-3. PubMed ID: 15603317
[TBL] [Abstract][Full Text] [Related]
6. Differences in fluid and solute transport between diabetic and nondiabetic patients at the onset of CAPD.
Serlie MJ; Struijk DG; de Blok K; Krediet RT
Adv Perit Dial; 1997; 13():29-32. PubMed ID: 9360646
[TBL] [Abstract][Full Text] [Related]
7. Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-I (PAI-I) levels in plasma and peritoneal effluent in patients on CAPD.
Selgas R; Cuesta MV; Riñon C; Romero JR; de Alvaro F; Bajo MA; Sanchez-Sicilia L
Adv Perit Dial; 1992; 8():160-5. PubMed ID: 1361777
[TBL] [Abstract][Full Text] [Related]
8. Differences in peritoneal equilibration test results in patients aged above or below 60 years.
Grzegorzewska AE; Leander M; Mariak I
Adv Perit Dial; 2002; 18():33-9. PubMed ID: 12402583
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal protein losses in diabetic patients starting peritoneal dialysis: is there a relationship with diabetic vascular lesions?
Coronel F; Cigarrán S; Herrero JA; Delgado J; Ramos F; Gomis A
Adv Perit Dial; 2009; 25():115-8. PubMed ID: 19886331
[TBL] [Abstract][Full Text] [Related]
10. Outcome for continuous ambulatory peritoneal dialysis patients is not predicted by peritoneal permeability characteristics.
Passadakis PS; Thodis ED; Panagoutsos SA; Selisiou CA; Pitta EM; Vargemezis VA
Adv Perit Dial; 2000; 16():2-6. PubMed ID: 11045251
[TBL] [Abstract][Full Text] [Related]
11. Comparison of peritoneal equilibration test with 2.27% and 3.86% glucose dialysis solution.
Cara M; Virga G; Mastrosimone S; Girotto A; Rossi V; D'Angelo A; Bonfante L
J Nephrol; 2005; 18(1):67-71. PubMed ID: 15772925
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal transport in type I (insulin-dependent) and type II (noninsulin-dependent) diabetic peritoneal dialysis patients.
Lin JJ; Wadhwa NK; Suh H; Cabralda T
Adv Perit Dial; 1995; 11():60-2. PubMed ID: 8534739
[TBL] [Abstract][Full Text] [Related]
13. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients.
Sezer S; Tutal E; Arat Z; Akçay A; Celik H; Ozdemir FN; Haberal M
J Ren Nutr; 2005 Oct; 15(4):427-34. PubMed ID: 16198934
[TBL] [Abstract][Full Text] [Related]
14. Transfer of native insulin through the peritoneal membrane during CAPD in non-diabetic and diabetic patients.
Ersoy FF; Karayalcin U; Karayalcin B; Sapan M; Bozcuk H; Süleymanlar G; Yakupoglu G
Adv Perit Dial; 1995; 11():119-22. PubMed ID: 8534683
[TBL] [Abstract][Full Text] [Related]
15. Transport of peritoneal membrane assessed before and after the start of peritoneal dialysis.
La Milia V; Limardo M; Cavalli A; Crepaldi M; Locatelli F
Nephrol Dial Transplant; 2009 Sep; 24(9):2894-8. PubMed ID: 19349295
[TBL] [Abstract][Full Text] [Related]
16. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis--a multicentre study in Japan.
Hirahara I; Inoue M; Okuda K; Ando Y; Muto S; Kusano E
Nephrol Dial Transplant; 2007 Feb; 22(2):560-7. PubMed ID: 17035369
[TBL] [Abstract][Full Text] [Related]
17. Relationship between dialysate oxidized protein and peritoneal membrane transport properties in patients on peritoneal dialysis.
Latcha S; Hong S; Gibbons N; Kohn N; Mattana J
Nephrol Dial Transplant; 2008 Oct; 23(10):3295-301. PubMed ID: 18443211
[TBL] [Abstract][Full Text] [Related]
18. Peritoneal fast transport in incident peritoneal dialysis patients is not consistently associated with systemic inflammation.
Rodrigues AS; Almeida M; Fonseca I; Martins M; Carvalho MJ; Silva F; Correia C; Santos MJ; Cabrita A
Nephrol Dial Transplant; 2006 Mar; 21(3):763-9. PubMed ID: 16332703
[TBL] [Abstract][Full Text] [Related]
19. Effects of glucose and plasminogen activator inhibitor-1 on collagen metabolism in the peritoneum.
Higuchi C; Tanihata Y; Nishimura H; Naito T; Sanaka T
Ther Apher Dial; 2005 Apr; 9(2):173-81. PubMed ID: 15828931
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator inhibitor-1 and diabetic nephropathy.
Lee HB; Ha H
Nephrology (Carlton); 2005 Oct; 10 Suppl():S11-3. PubMed ID: 16174279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]